Business
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
Ad hoc announcement pursuant to Art. 53 LRBASEL, Switzerland, March 18, 2026 (GLOBE NEWSWIRE) -- Significant clinical and regulatory progress across entire pipeline BV100: Initiated global registrational Phase 3 (RIV-TARGET) in HABP/VABP1 program – US FDA green lights INDPhase 2b (RIV-CARE) to be conducted via Wellcome-funded trial network ADVANCE-IDFirst participants dosed in Phase 1 in China, preparing onboarding of China into RIV-TARGETBV100 patent granted in China, adding to BV100’s patent c
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"BioVersys","displaySize":"","headline":null,"caption":"BioVersys","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Zo6ExiGAEwq5bzAtMXIVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47","width":300,"height":65},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/_Zo6ExiGAEwq5bzAtMXIVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47","width":300,"height":65}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"BASEL, Switzerland, March 18, 2026 (GLOBE NEWSWIRE) --","length":54,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Significant clinical and regulatory progress across entire pipeline","length":67,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":67,"olType":false},{"type":"text","content":"BV100:","length":6,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Initiated global registrational Phase 3 (RIV-TARGET) in HABP/VABP1 program – US FDA green lights IND","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2b (RIV-CARE) to be conducted via Wellcome-funded trial network ADVANCE-ID","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"First participants dosed in Phase 1 in China, preparing onboarding of China into RIV-TARGET","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"BV100 patent granted in China, adding to BV100’s patent coverage in over 25 countries including the US and Europe ","length":113,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":384,"olType":false},{"type":"text","content":"Alpibectir: ","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Our partner GSK reported first patient first visit for Phase 2b/c trial in pulmonary TB ","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2a results published in New England Journal of Medicine","length":61,"tagName":"p"}]},{"val":[{"type":"text","content":"Received EMA Orphan Designatio...